Blog
RSS FeedPosted by Michael Wonder on 02 Jun 2022
Biogen and Samsung Bioepis’ Byooviz (ranibizumab-nuna) launches in the United States
2 June 2022 - Byooviz, priced 40% lower than Lucentis, provides an equally effective and more affordable treatment option to patients ...
Posted by Michael Wonder on 22 May 2022
Patients deserve immediate access to FDA approved innovations — not bureaucratic restrictions
21 May 2022 - Innovation is the lifeblood that has made America the most economically successful nation in the modern era. ...
Posted by Michael Wonder on 10 Mar 2022
When desperate patients go to court for unproven treatments - the battle for hospital independence
9 March 2022 - During the COVID-19 pandemic, patients have asked courts to compel hospitals to administer unproven therapies, including ivermectin. ...
Posted by Michael Wonder on 07 Mar 2022
Teva announces launch of a first generic version of Revlimid (lenalidomide capsules) in the U.S.
7 March 2022 - Teva Pharmaceuticals announced today the launch of a first generic version of Revlimid (lenalidomide capsules), in 5 ...
Posted by Michael Wonder on 22 Feb 2022
The truth about patient access and FDA fast tracking
21 February 2022 - University of Illinois Chicago researchers studied 135 products that received U.S. FDA approval through orphan drug and ...
Posted by Michael Wonder on 22 Jan 2022
Patent thickets are thwarting U.S. availability of lower cost biosimilar medicines, study finds
18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...
Posted by Michael Wonder on 16 Nov 2021
Viatris and Biocon Biologics announce launch of interchangeable Semglee (insulin glargine-yfgn) injection and insulin glargine (insulin glargine-yfgn) injection
16 November 2021 - Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for ...
Posted by Michael Wonder on 29 Sep 2021
Global disparity in access to novel therapeutics for metastatic prostate cancer
29 September 2021 - Access to androgen receptor directed therapies, which also have life-prolonging benefits in the castration-resistant prostate cancer ...
Posted by Michael Wonder on 24 Aug 2021
FDA approves expanded peripheral artery disease indication for Xarelto (rivaroxaban) plus aspirin to include patients after lower extremity revascularisation due to symptomatic peripheral artery disease
24 August 2021 - Xarelto is the first and only therapy indicated for both coronary artery disease and peripheral artery disease, ...
Posted by Michael Wonder on 17 Jun 2021
A life-saving new drug for COVID-19 is found
16 June 2021 - But only rich countries will benefit, and even they will struggle to get hold of it. ...
Posted by Michael Wonder on 13 Jun 2021
Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls
11 June 2021 - When Eli Lilly announced in 2017 that it would stop producing quinidine, it was the only ...
Posted by Michael Wonder on 08 Jun 2021
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access Aduhelm
7 June 2021 - Value based agreements in progress with Cigna and other payers. ...
Posted by Michael Wonder on 05 Jun 2021
Newly approved obesity drug Wegovy holds promise, but faces reimbursement challenges
5 June 2021 - On 4 June, the FDA approved Novo Nordisk’s obesity drug Wegovy (semaglutide), a glucagon-like peptide 1 receptor ...
Posted by Michael Wonder on 12 May 2021
Public availability of results of ClinicalTrials.gov registered expanded access studies
10 May 2021 - Expanded access is the use of investigational treatments outside of clinical trials. Results of expanded access studies ...
Posted by Michael Wonder on 20 Apr 2021
Amgen launches Biomarker Assist, a program to help more patients with non-small cell lung cancer gain access to biomarker testing
19 April 2021 - Half of all patients with non-small cell lung cancer have oncogene mutations, yet many patients are not ...